Rusfertide Shows Significant Improvements in Patient Outcomes for Polycythemia Vera in Pivotal Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 02 2026
0mins
Should l Buy PTGX?
Source: Newsfilter
- Clinical Response Rate Increase: In the Phase 3 VERIFY study, the combination of Rusfertide and standard care more than doubled clinical response rates, exceeding 50%, indicating its significant potential in treating polycythemia vera.
- Good Safety and Tolerability: Rusfertide demonstrated good tolerability over 52 weeks, with injection site reactions at 47.4% and serious adverse events at only 8.1%, laying a solid foundation for its future market introduction.
- FDA Priority Review: The U.S. FDA has accepted the New Drug Application for Rusfertide and granted Priority Review, with a decision expected in Q3 2024, which will expedite its market entry and address the urgent need for new therapies.
- Strengthened Partnership: The global licensing and collaboration agreement between Takeda and Protagonist will drive the commercialization of Rusfertide, enhancing both companies' ability to meet the treatment needs of patients with polycythemia vera.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PTGX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PTGX
Wall Street analysts forecast PTGX stock price to fall
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 98.850
Low
65.00
Averages
94.54
High
115.00
Current: 98.850
Low
65.00
Averages
94.54
High
115.00
About PTGX
Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on peptide therapeutics. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The Company also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Protagonist Therapeutics Gains FDA Approval, Strong Upside Potential
- Investor Interest: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) has been a consistent presence in Farallon Capital's 13F portfolio since Q4 2017, with shares increasing from 900,000 to 6.1 million, reflecting institutional confidence in its long-term potential.
- Product Innovation: The company’s Icotyde, a first-in-class oral peptide for moderate-to-severe plaque psoriasis, has gained FDA approval and commercial launch, making it the only once-daily oral IL-23R peptide on the market, which poses a significant threat to existing injectable biologics.
- Financial Incentives: The FDA approval triggered a $50 million milestone payment this quarter, with the potential for an additional $580 million in future regulatory and sales milestones, significantly enhancing the company's financial position and market competitiveness.
- Market Strategy: By partnering with Johnson & Johnson, Protagonist can leverage J&J's extensive global marketing efforts to collect high-margin royalties without the overhead of a sales force, thereby optimizing resource allocation and enhancing profitability.
See More
PROTAGONIST THERAPEUTICS INC: CLEAR STREET INCREASES TARGET PRICE TO $116, UP FROM $104
- Price Increase Announcement: The price of Protagenic Therapeutics' stock has been raised to $116 from $104.
- Market Reaction: This adjustment reflects a significant change in the company's market valuation and investor sentiment.
See More
Johnson & Johnson Divests from 3 Biotech Companies While Retaining Investments in Potential Acquisition Candidates
Johnson & Johnson's Holdings Report: The company has restated its fourth-quarter holdings report, which was filed last week.
Exit from Biotechs: Johnson & Johnson has exited three biotech companies as part of its portfolio adjustments.
Retention of Stakes: Despite the exits, the company has retained its stakes in several rumored acquisition targets.
Strategic Moves: These actions indicate a strategic shift in Johnson & Johnson's investment approach within the biotech sector.
See More
Insider at Protagonist Therapeutics (PTGX.US) Plans to Sell $5.39 Million in Common Stock via Form 144
Stock Sale Announcement: Dinesh Patel plans to sell 54,700 shares of Protagonist Therapeutics (PTGX.US) on March 24, with a total market value of approximately $5.39 million.
Reduction in Holdings: Patel has reduced his shareholding in Protagonist Therapeutics by 48,273 shares since January 23, 2026, valued at around $4.06 million.
See More
RTW Investments Takes New Stake in Apellis Pharmaceuticals
- New Investment Move: RTW Investments initiated a new position in Apellis Pharmaceuticals during Q4 2026, acquiring 7,666,764 shares valued at $192.59 million, indicating confidence in the biotech firm’s future prospects.
- Market Performance Analysis: Currently priced at $17.21, Apellis shares have declined 29% over the past year, significantly underperforming the S&P 500, which has risen 15% in the same period, reflecting market caution regarding its growth trajectory.
- Revenue and Growth Potential: Apellis generated approximately $689 million in product revenue last year, with its flagship therapy alone contributing about $587 million, demonstrating real demand and potential for market share expansion in the rare disease sector.
- Portfolio Strategy: Apellis accounts for 1.93% of RTW's reportable AUM, suggesting a strategic pivot towards more stable revenue streams while still maintaining exposure to high-growth opportunities within its broader investment portfolio.
See More
RTW Investments Increases Stake in Cogent Biosciences by $116 Million
- Stake Increase: RTW Investments disclosed an acquisition of 4,124,755 shares of Cogent Biosciences in its February 17, 2026 SEC filing, with an estimated transaction value of $115.95 million, indicating strong confidence in the company's future prospects.
- Market Performance: Cogent Biosciences' stock has surged 360% over the past year, compared to a mere 15% gain for the S&P 500, highlighting significant market anticipation for its potential drug launches and positive investor sentiment.
- Financial Position: Currently, Cogent has a market capitalization of $5.4 billion, and despite a net income of -$328.94 million, it boasts approximately $900 million in cash reserves, providing ample runway for R&D and clinical trials through 2028.
- Strategic Implications: The increase in RTW's stake to 2.7% reflects confidence in high-risk biotech investments, particularly with upcoming FDA reviews, where successful clinical outcomes could further propel the stock price upward.
See More
Protagonist Therapeutics Gains FDA Approval, Strong Upside Potential
- Investor Interest: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) has been a consistent presence in Farallon Capital's 13F portfolio since Q4 2017, with shares increasing from 900,000 to 6.1 million, reflecting institutional confidence in its long-term potential.
- Product Innovation: The company’s Icotyde, a first-in-class oral peptide for moderate-to-severe plaque psoriasis, has gained FDA approval and commercial launch, making it the only once-daily oral IL-23R peptide on the market, which poses a significant threat to existing injectable biologics.
- Financial Incentives: The FDA approval triggered a $50 million milestone payment this quarter, with the potential for an additional $580 million in future regulatory and sales milestones, significantly enhancing the company's financial position and market competitiveness.
- Market Strategy: By partnering with Johnson & Johnson, Protagonist can leverage J&J's extensive global marketing efforts to collect high-margin royalties without the overhead of a sales force, thereby optimizing resource allocation and enhancing profitability.
See More
PROTAGONIST THERAPEUTICS INC: CLEAR STREET INCREASES TARGET PRICE TO $116, UP FROM $104
- Price Increase Announcement: The price of Protagenic Therapeutics' stock has been raised to $116 from $104.
- Market Reaction: This adjustment reflects a significant change in the company's market valuation and investor sentiment.
See More
Johnson & Johnson Divests from 3 Biotech Companies While Retaining Investments in Potential Acquisition Candidates
Johnson & Johnson's Holdings Report: The company has restated its fourth-quarter holdings report, which was filed last week.
Exit from Biotechs: Johnson & Johnson has exited three biotech companies as part of its portfolio adjustments.
Retention of Stakes: Despite the exits, the company has retained its stakes in several rumored acquisition targets.
Strategic Moves: These actions indicate a strategic shift in Johnson & Johnson's investment approach within the biotech sector.
See More
Insider at Protagonist Therapeutics (PTGX.US) Plans to Sell $5.39 Million in Common Stock via Form 144
Stock Sale Announcement: Dinesh Patel plans to sell 54,700 shares of Protagonist Therapeutics (PTGX.US) on March 24, with a total market value of approximately $5.39 million.
Reduction in Holdings: Patel has reduced his shareholding in Protagonist Therapeutics by 48,273 shares since January 23, 2026, valued at around $4.06 million.
See More
RTW Investments Takes New Stake in Apellis Pharmaceuticals
- New Investment Move: RTW Investments initiated a new position in Apellis Pharmaceuticals during Q4 2026, acquiring 7,666,764 shares valued at $192.59 million, indicating confidence in the biotech firm’s future prospects.
- Market Performance Analysis: Currently priced at $17.21, Apellis shares have declined 29% over the past year, significantly underperforming the S&P 500, which has risen 15% in the same period, reflecting market caution regarding its growth trajectory.
- Revenue and Growth Potential: Apellis generated approximately $689 million in product revenue last year, with its flagship therapy alone contributing about $587 million, demonstrating real demand and potential for market share expansion in the rare disease sector.
- Portfolio Strategy: Apellis accounts for 1.93% of RTW's reportable AUM, suggesting a strategic pivot towards more stable revenue streams while still maintaining exposure to high-growth opportunities within its broader investment portfolio.
See More
RTW Investments Increases Stake in Cogent Biosciences by $116 Million
- Stake Increase: RTW Investments disclosed an acquisition of 4,124,755 shares of Cogent Biosciences in its February 17, 2026 SEC filing, with an estimated transaction value of $115.95 million, indicating strong confidence in the company's future prospects.
- Market Performance: Cogent Biosciences' stock has surged 360% over the past year, compared to a mere 15% gain for the S&P 500, highlighting significant market anticipation for its potential drug launches and positive investor sentiment.
- Financial Position: Currently, Cogent has a market capitalization of $5.4 billion, and despite a net income of -$328.94 million, it boasts approximately $900 million in cash reserves, providing ample runway for R&D and clinical trials through 2028.
- Strategic Implications: The increase in RTW's stake to 2.7% reflects confidence in high-risk biotech investments, particularly with upcoming FDA reviews, where successful clinical outcomes could further propel the stock price upward.
See More
